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Cardiac Magnetic Resonance
Imaging Study for Quantification of Infarct
Size Comparing Directly Serial Versus Single
Time-Point Measurements of Cardiac Troponin T
Evangelos Giannitsis, MD,* Henning Steen, MD,* Kerstin Kurz, MD,* Boris Ivandic, MD,*
Anke C. Simon, MD,* Simon Futterer, MD,* Christian Schild, MD,* Peter Isfort, MD,*
Allan S. Jaffe, MD, FACC,† Hugo A. Katus, MD, FACC*
Heidelberg, Germany; and Rochester, Minnesota
Objectives We compared single-point cardiac troponin T (cTnT) measurements with parameters from serial sampling during
96 h after acute myocardial infarction with magnetic resonance imaging measured infarct mass.
Background Contrast-enhanced magnetic resonance imaging (CE-MRI) allows exact quantification of myocardial infarct size.
Clinically, measurement of cardiac biomarkers is a more convenient alternative.
Methods The CE-MRI infarct mass was determined 4 days after primary percutaneous coronary intervention in 31 ST-
segment elevation myocardial infarction (STEMI) and 30 non–ST-segment elevation myocardial infarction
(NSTEMI) patients. All single-point, peak, and integrated area under the curve (AUC) cTnT values were plotted
against CE-MRI infarct mass.
Results All single-point and serial cTnT values were significantly higher in STEMI than in NSTEMI (p  0.01) patients.
Except for the admission values, all single-point values on any of the first 4 days, peak cTnT and AUC cTnT were
found to correlate comparably well with infarct mass. Among single-point measurements, cTnT on day 4
(cTnTD4) showed highest correlation and performed as well as peak cTnT or AUC cTnT (r  0.66 vs. r  0.65 vs.
r  0.69). Receiver-operator characteristic analysis demonstrated that cTnTD4 0.84 g/l predicted infarct
mass above median as well as peak cTnT 1.57 g/l or AUC cTnT (receiver-operator characteristic for AUC:
0.839 vs. 0.866 vs. 0.893). However, estimation of infarct mass with cTnTD4, peak cTnT, and AUC cTnT was
worse in patients with NSTEMI (r  0.36, r  0.5, r  0.36) than in STEMI (r  0.75 vs. r  0.65 vs. r  0.76).
Conclusions All single-point cTnTs, except on admission, give a good estimation of infarct size and perform as well as peak
cTnT or AUC cTnT. Infarct estimation by single-point measurements, particularly cTnTD4, may gain clinical accep-
tance because the measurement is easy and inexpensive. (J Am Coll Cardiol 2008;51:307–14) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.041e
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qrognosis after acute myocardial infarction (AMI) is
trongly determined by the extent of myocardial injury (1).
urrently, several imaging techniques, including thallium
estamibi, positron emission tomography, and contrast-
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ompanies. Drs. Giannitsis and Steen contributed equally to this article.h
Manuscript received March 23, 2007; revised manuscript received August 10, 2007,
ccepted September 7, 2007.nhanced magnetic resonance imaging (CE-MRI), are used
or quantification of infarct size (2). Among these tech-
iques, some prefer cardiovascular magnetic resonance
CMR) imaging because it allows noninvasive assessment of
yocardial function and viability with high spatial resolu-
ion and is superior to single-photon emission computed
omography (SPECT) for the identification of subendocar-
ial AMI (3,4). Furthermore, the technique is highly
ensitive and permits quantification of small areas of myo-
ardial injury attributable to native coronary artery disease
nd/or percutaneous coronary interventions (5,6). However,
he use of cardiac magnetic resonance (MR) imaging for
uantification of infarct size is limited by availability and
igh cost. Therefore, estimating infarct size from concen-
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MRI and cTnT Infarct Size January 22, 2008:307–14trations or activities of cardiac
proteins in peripheral blood, as
has been done for years, is a
convenient alternative (2).
Previous work depended on
creatine kinase-MB fraction
(CK-MB), but it is now clear
that cardiac troponin T (cTnT)
or cardiac troponin I (cTnI) pos-
sess better sensitivity and speci-
ficity and are, therefore, the pre-
ferred markers for diagnosis and
risk stratification of patients with
acute coronary syndrome and
AMI (7,8). There is strong evi-
dence to indicate that both serial
and single-point measurements
of cTnT correlate well with in-
farct size as measured at post-
mortem in animal experiments
(9,10) and/or with various imag-
ing techniques in clinical studies
(11–13). However, MR imaging
studies to determine the optimal
timing for single-point measure-
ments and compare such mea-
surements to serial measure-
ments are currently not available.
Accordingly, the present study
sought to determine the best
single-measurement time point
and its performance as compared
o peak and cumulative cTnT values (area under the curve
AUC]) values after AMI. Peak and AUC values were
etermined from daily serial sampling over 96 h, and all
alues were correlated to infarct size that was quantified
sing contrast-enhanced CE-MRI.
ethods
atients. Only patients with first AMI were enrolled.
sing 12-lead standard electrocardiogram, AMI patients
ere categorized into acute ST-segment elevation myo-
ardial infarction (STEMI) and non–ST-segment eleva-
ion myocardial infarction (NSTEMI). We defined
TEMI by the presence of ST segment elevation 0.1
V in unipolar leads or elevation 0.2 mV in anterior
all leads and was retrospectively confirmed by elevated
TnT above 0.03 g/l. Non–STEMI was defined using
he diagnostic criteria of the European Society of Cardi-
logy/American Heart Association Task Force on Myo-
ardial Infarction and required an elevation of cTnT
bove 0.03 g/l, which is the 10% coefficient of variation
alue for this assay used clinically at our institution on at
east 1 occasion within 24 h after the ischemic index
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
AUC  area under the
curve
CE-MRI  contrast-
enhanced magnetic
resonance imaging
CI  confidence interval
CK-MB  creatine kinase-
MB fraction
CMR  cardiovascular
magnetic resonance
cTnI/T  cardiac troponin I
or T
MR  magnetic resonance
MRI  magnetic resonance
imaging
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
ROC  receiver-operator
characteristic
SPECT  single-photon
emission computed
tomography
STEMI  ST-segment
elevation myocardial
infarctionvent, with a rise or fall during subsequent sampling (8). iatients with renal failure having a glomerular filtration
ate below 60 ml/min/1.73 m2 were excluded because it
ight result in overestimation of infarct size and because
f potential toxicity related to gadolinium use (14). Blood
amples were taken on admissions and daily for 96 h.
fter collection, blood samples were centrifuged imme-
iately and serum was stored at 20°C until analysis. We
easured cTnT on the same Elecsys analyzer (Roche
iagnostics, Mannheim, Germany) using the third-
eneration assay (15). The detection limit of the assay is
.01 g/l. The decision limit used for diagnosis of AMI
s 0.03 g/l, with an imprecision of 10%. The labora-
ory staff responsible for measurements were blinded to
he patient data.
We measured single-point cTnT at admission and after
4, 48, 72, and 96 h. Peak cTnT and cumulative cTnT over
6 h were determined retrospectively from serial samples. A
alue was defined as peak if it was the highest in the
oncentration time course and if there was at least 1 lower
alue before and after this maximum value.
All decisions regarding acute reperfusion therapy and
linical management of patients were left to the discretion of
he attending cardiologist, who was not involved in the
tudy. The study protocol was approved by the local ethical
ommittee of the University of Heidelberg, and all patients
ave informed consent before study enrollment.
Cardiac magnetic resonance imaging (MRI) was per-
ormed in all patients before discharge unless they had
ontraindications, withdrew their consent, experienced
laustrophobia, or reported shortness of breath prohibiting
dequate breath holding during the MRI examination.
E-MRI. Cardiac MRI was performed in a 1.5-T
hole-body MRI scanner (Philips Achieva Intera, Phil-
ps, Best, the Netherlands). Assessment of resting left
entricular function was determined by cine images using
steady-state free precession sequence in continuous
hort-axes planes covering the whole left ventricle from
ase to apex, as well as 2- and 4-chamber views. Ten
inutes after gadolinium contrast injection (Gd  0.2
mol/kg of gadopentetate dimeglumine [Schering, Ber-
in, Germany]), 3 volume stacks of delayed contrast-
nhanced images covering the whole left ventricle were
lanned on previous short-, 2-, and 4-chamber axes.
nd-diastolic and -systolic volumes with resulting ejec-
ion fraction were generated manually using short-axes
olumetry. Infarct size was visually defined as area of
elayed hyperenhancement on short-axes views and de-
ermined manually by delineation of hyperenhanced ver-
us normally saturated dark myocardium. Magnetic res-
nance imaging analysis included quantification of
bsolute infarct size (g) and left ventricular function in all
atients.
tatistical analysis. Means with standard deviation or
edians with 25th and 75th percentiles were calculated to
escribe continuous variables. Given that cTnT values and
nfarct size values were not normally distributed, correla-
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January 22, 2008:307–14 MRI and cTnT Infarct Sizeions were calculated using Spearman rank correlation.
aired and unpaired correlations were analyzed for differ-
nces using z-statistics. Receiver-operator characteristic
ROC) curves were constructed to examine the relationship
etween biomarker estimates and CE-MRI infarct size. For
OC analysis, the patients were categorized into 2 data sets:
hose with CE-MRI infarct size above median and those
elow median. Finally, multivariate logistic regression anal-
sis was performed to test for significant predictors of infarct
ize, including variables with a univariate p  0.1. For all
nalyses, a p value 0.05 was regarded as statistically
ignificant. All statistical analyses were performed using
edCalc Version 9.2 for Windows (MedCalc Software,
ariakerke, Belgium).
esults
atients. A total of 61 patients with AMI were included.
f these, 31 patients had a STEMI and 30 patients had a
STEMI. Median time from onset of symptoms to reper-
usion was 477 min (95% confidence interval [CI] 252.7
o 608.6 min) for the entire cohort, 224 min (95% CI 124.2
o 362.1 min) for STEMI, and 709.5 min (95% CI 516.9 to
,332.75 min) for NSTEMI. Median door-to-balloon-
imes were 77.5 min (95% CI 49.95 to 124.6 min) for the
ntire cohort, 46.5 min (95% CI 35.4 to 70.4 min) for
TEMI, and 221 min (95% CI 129.1 to 377.3 min) for
STEMI.
On initial angiogram, patients with STEMI tended to
ore often have an occluded infarct-related artery (Throm-
olysis In Myocardial Infarction flow grade 0 or 1) than
atients with NSTEMI (61.3% vs. 43%, p 0.08). Primary
ercutaneous coronary intervention (PCI) in STEMI or
arly PCI in NSTEMI patients was attempted in 60 of 61
atients and was successful in 58 of 61 patients (95.1%).
eperfusion success, defined as post-procedural Thrombol-
sis In Myocardial Infarction flow grade 2 or 3, was
omparable in STEMI and NSTEMI (96.8% vs. 93.3%).
Baseline clinical characteristics of the entire study popu-
ation are displayed in Table 1.
RI results. We performed CE-MRI after a median of 4
ays (range 3 to 4). Patients with a STEMI had a signifi-
antly higher mean infarct mass (mean [95% CI]: 34.24 g
23.19 to 45.29 g) vs. 12.61 g (7.79 to 17.44 g), p 
.0009], relative infarct size (20.32% [15.24 to 25.40] vs.
.05% [5.53 to 10.56], p  0.0001), and a trend to lower
V ejection fraction (54.45% [50.53 to 58.37] vs. 60.21%
56.60 to 63.83], p  0.089).
iomarker results. A total of 280 samples were obtained
rom 61 patients, yielding a mean of 4.6 samples per patient.
edian cTnT values with corresponding 95% CI for the
edian were 1.7 g/l (1.09 to 2.5) on day 1, 1.64 g/l (1.01
o 1.98) on day 2, 1.49 /l (0.93 to 1.89) on day 3, 1.27 g/l
0.82 to 1.81) on day 4, and 23.0 g/l (19 to 27.82) for peak
TnT value. 0By infarct type, single-point cTnT values at 24 h (2.67
g/l vs. 0.6 g/l, p  0.0001), 48 h (2.1 g/l vs. 1.07
g/l, p  0.0019), 72 h (2.02 g/l vs. 0.83 g/l, p 
.0017), and 96 h (1.86 g/l vs. 0.76 g/l, p  0.027)
ere significantly higher in STEMI than in NSTEMI.
ikewise, serial values, including AUC cTnT, (203.3 vs.
3.4, p  0.0006), peak cTnT (3.08 g/l vs. 1.08 g/l,
 0.0001), peakCKact (1,645 IU vs. 739 IU, p 
linical Characteristics
Table 1 Clinical Characteristics
All n  61
Men, n (%) 51 (82.26)
Age (yrs) 58 (12)
Age 70 yrs, n (%) 10 (16.4)
Creatinine clearance, ml/min/1.73 m2 107.3 (30.5)
Previous MI, n (%) 1 (1.6)
Previous PCI, n (%) 10 (16.4)
Previous CABG, n (%) 1 (1.6)
Infarct type, n (%)
STEMI 31 (50.8)
NSTEMI 30 (49.2)
Infarct location, n (%)
Anterior 27 (44.3)
Nonanterior 34 (55.7)
Infarct-related artery, n (%)
LAD 27 (44.3)
LCX 10 (16.4)
RCA 23 (37.7)
CABG 1 (1.6)
Symptom-to-admission (min)
All 200.5 (159.95–354.26)
STEMI 162.5 (82.00–265.36)
NSTEMI 352.5 (181.32–591.75)
Door-to-balloon (min)
All 77.5 (49.95–124.6)
STEMI 46.5 (35.4–70.4)
NSTEMI 221 (129.1–377.3)
TIMI flow grade baseline, n (%)
0 29 (47.5)
1 3 (4.9)
2 9 (14.8)
3 20 (32.8)
TIMI flow grade after PCI, n (%)
0 3 (4.9)
2 10 (16.4)
3 48 (78.7)
Procedural success n (%) 58 (95.1)
Coronary risk factors
BMI (kg/m2) 27 (3)
Hypertension, n (%) 39 (62.9)
Hypercholesterolemia, n (%) 41 (66.1)
Diabetes mellitus, n (%) 9 (14.5%)
Fam. disposition, n (%) 26 (40.94%)
Current smoker, n (%) 29 (46.8%)
MI  body mass index; CABG  coronary artery bypass graft; LAD  left anterior descending;
CX  left circumflex; MI  myocardial infarction; NSTEMI  non–ST-segment elevation myocar-
ial infarction; PCI  percutanous coronary intervention; RCA  right coronary artery; STEMI 
T-segment elevation myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction..0008), and peak CK-MB mass (40.8 g/l vs. 24.9 g/l,
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MRI and cTnT Infarct Size January 22, 2008:307–14 0.043), were significantly higher in STEMI than in
STEMI. Consistently, time-to-peak cTnT values (20.5
vs. 36.5 h, p  0.0025) were shorter in STEMI than in
STEMI.
Regression coefficients measured by Spearman rank cor-
elation between biomarker estimates and absolute MRI
nfarct mass for the entire cohort are displayed in Figure 1.
Measurements of cTnT on any single point after admis-
ion correlated comparably well with infarct mass and were
ot different from peak cTnT or integration of the AUC
rom serial sampling.
The ROC analysis displays the performance of cTnT at
6 h, peak, and AUC values for prediction of infarct size
bove median, that is, 13.6 g (Fig. 2), demonstrating similar
UC values for cTnT at 96 h, peak cTnT, and AUC cTnT.
mpact of infarct size on performance of biomarker
stimates. Three categories were formed to test the impact
f infarct size on the performance of biomarker estimates.
pearman correlation coefficients between biomarker esti-
ate and categories were compared (Table 2). Patients with
STEMI or CE-MRI infarct size below the median (13.6
) showed a substantially worse performance of cTnT than
atients with STEMI, anterior MI, or non-anterior MI.
ultivariate analysis for prediction of infarct size. All
ignificant univariate predictors were included in the mul-
iple logistic regression model to examine their independent
redictive value for estimation of infarct size above median
13.6 g). Keeping all other variables constant, all single-
oint and peak cTnT were tested to obtain the model with
he highest chi-square value. In this final model, cTnT on
ay 4 and presence of STEMI versus NSTEMI were the
nly independent significant predictors of larger infarct size
Table 3). A secondary analysis within STEMI or
STEMI gave no meaningful results owing to the small
umber of patients.
iscussion
ur data indicate that measurement of cTnT at a single
oint on any of the first 4 days or using the peak-value
orrelates well with infarct mass determined by CE-MRI.
hese data points perform as well as serial sampling
stimates, including integration of AUC. We would suggest
hat the 96-h value would be convenient to use clinically,
nd it would be helpful for clinical trials to also use a similar
alue. However, correlations of all values are similar, al-
hough with a different slope, so clinicians can use any of the
esults if they so choose, and with time they should be able
o develop a good estimate for infarct size.
Our results are not nearly as robust in patients with small
nfarcts, and that is likely the reason for the poorer corre-
ations with NSTEMI, which were smaller by both cTnT
easurements and by CE-MRI. This may be related to the
ariety of pathophysiologies that exist in patients with
STEMI (16). In addition, however, microinfarcts associ-ted with minor elevations of cTnT may escape visualiza- iion with CE-MRI or be difficult to quantify owing to
nsufficient visualization caused by inadequate spatial reso-
ution or partial volume effects. Interestingly, Ricciardi et al.
5) found more promising results with visualization of a
ean infarct size as low as 2.0 g. In that study, 5 of 9
atients with late hyperenhancement had suffered a side-
ranch occlusion during PCI, but none developed Q-wave
nfarction. Interestingly, new wall motion abnormalities
ere detected in only 1 patient with late hyperenhancement.
he reason for this disparity is unclear but may involve the
se of a single breath-hold 3-dimensional inversion recovery
equence with slightly lower spatial resolution in our study,
nd, conversely, a potential underestimation of infarct size
ecause of incomplete coverage of the left ventricle coming
rom single-slice inversion recovery technique in the study
f Ricciardi et al. (5).
ingle versus serial cTnT for estimation of AMI. The
ost accurate methods for estimation of infarct size in the
re-reperfusion era were based on complete recovery of CK
r its isoforms (17,18) or LD isoenzymes released from the
nfarcted myocardial tissue (19,20). Measurement of maxi-
um enzyme values of CK or CK-MB proves convenient
ut has a propensity to overestimate infarct size, particularly
hen spontaneous reperfusion, PCI, or thrombolysis-
nduced reperfusion leads to an earlier and higher maximum
K level at identical amounts of left ventricular impairment
21–23). In addition, the peak value is influenced by release
atio, which is much higher after reperfusion (24); the
lasma half-life of the cardiac constituent (25); and the
agnitude of the AMI itself (26–28). In addition, CK and,
o a lower extent, CK-MB mass lack absolute cardiospeci-
city, thus increasing the likelihood of overestimation of
nfarct size attributable to skeletal muscle damage. Other
nvestigators have advocated for lactate dehydrogenase,
hich is cardio-unspecific, or the more cardiospecific deriv-
tive hydroxybutyrate dehydrogenase (HBDH) because
hese enzymes demonstrate a slower release from the myo-
yte and may manifest a more consistent release ratio
espite successful reperfusion (19). By using HBDH at
2 h, others have found (20) minimal underestimation of
nfarct size compared to HBDH at 96 or 120 h. However,
s noted by Sobel et al. (29), there is substantial HBDH in
ed cells, and hemorrhage can occur after reperfusion,
onfounding this measure of infarct size as well.
At present, the cardiac troponins are the preferred cardiac
arkers for the diagnosis of AMI owing to their superior
ensitivity and specificity (8). In addition, unlike the small
ytosolic cTnT fraction that may be prone to an accelerated
elease from the infarcted myocardium after successful
eperfusion, the majority of the protein resides in the
radually released structurally bound fraction that manifests
more consistent release ratio (21,30). Experimental work
as shown that the increases in serum troponin parallel the
oss in tissue concentrations of troponin (31) and that blood
alues of cardiac troponin T correlate with histochemical
nfarct size in the non-reperfused experimental AMI (9,10).
311JACC Vol. 51, No. 3, 2008 Giannitsis et al.
January 22, 2008:307–14 MRI and cTnT Infarct SizeFigure 1 Correlation Coefficients
Plots showing correlation by Spearman rank correlation between contrast-enhanced magnetic resonance imaging infarct mass and cardiac troponin T (cTnT) concentra-
tions during the entire sampling period (A), for any single-point (B to E), for peak cTnT (F), and cumulative cTnT over 96 h (cTnT area under the curve [AUC]) (G). Corre-
lation coefficients are displayed with corresponding 95% confidence intervals. The z-statistics show no statistical difference across any single-point cTnT between Day (D) 1
and Day 4.
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MRI and cTnT Infarct Size January 22, 2008:307–14nterestingly, single-point measurements at 96 h after left
nterior descending coronary artery ligation were as effective
s measurement of cumulative release requiring tight serial
ampling over 120 h or peak concentrations with retrospec-
ive location of the peaks, requiring at least 3 samples (9).
onsistently, an increasing number of imaging studies have
onfirmed that the more convenient single-point cTnT or
TnI perform as well as cumulative release in humans
11–13). The SPECT or CE-MRI infarct size has been
ound to correlate well with single-point values of cTnT at
pproximately 72 h (12,13) and 96 h (11) and with
ingle-point values of cTnI between 24 and 48 h (13,32).
his is likely a reflection of the stability of the release ratio
elated to the structurally bound pool.
In the present study, the best single-point cTnT value
as identified at 96 h and performed as effectively as peak
TnT and AUC cTnT over 96 h. For the latter, it is
Figure 2 ROC Curve Analysis for cTnT D4, cTnT Peak, and AUC
cTnT for Prediction of Infarct Mass Above Median
Receiver-operator characteristic (ROC) curve analysis for cTnT D4, cTnT peak,
and cTnT AUC for prediction of infarct mass above median demonstrates a
comparable performance of best single-point versus serial measurements. Dis-
play of ROC analysis include optimized cutoff concentrations and AUC with cor-
responding 95% confidence intervals. Other abbreviations as in Figure 1.
Performance of Biomarker Estimates of Infarct S
Table 2 Performance of Biomarker Estimate
AUC TnT
Infarct type
STEMI 0.76* (0.52–0.89), n 25
NSTEMI 0.36* (0.05–0.67), n 24
Infarct location
Anterior 0.76 (0.48–0.89), n 21
Nonanterior 0.59 (0.29–0.79), n 28
Infarct mass (CE-MRI)
Large MI 0.58‡ (0.23–0.79), n 24
Small MI 0.017‡ (0.38–0.41), n 25
Results are displayed as Spearman correlation coefficients with corre
STEMI and NSTEMI regarding AUC cTnT; †p  0.046 for the differen
difference between STEMI and NSTEMI regarding cTnT D4.
AUC  area under the curve; D4  Day 4; TnT  troponin T; other abbreviaeasonable to speculate that performance of cumulative
easurements could be improved by expansion of serial
easurements beyond 96 h. However, prolongation of
ampling is likely to reduce the attractiveness and accep-
ance of the method.
In the multivariate logistic regression analysis, high cTnT
alues and presence of STEMI emerged as significant
ndependent predictors of larger infarct size. Interestingly,
V ejection fraction, which was preserved in most patients,
ailed to predict infarct size. This may be attributable to the
act that we could include only patients with first infarc-
ions, and those who could not breath-hold because of
espiratory difficulties could not be imaged.
erformance of single or serial cTnT in small AMI. In
ur study, prediction of infarct size with either single or
erial cTnT was considerably better in patients with
arger CE-MRI infarct size (i.e., mean infarct mass 34.24
in STEMI) compared with smaller infarct size includ-
ng NSTEMI, non-anterior infarct location, or CE-MRI
nfarct size below median (mean infarct mass 12.61 g,
8 g, and 13.6 g, respectively). A previous report had
lready alluded to the finding that correlation between
nfarct size and cTnT measured 72 to 96 h after infarct
nset is inferior in NSTEMI than in STEMI (10). It has
een speculated that the poorer correlation was due to
uboptimal timing of sampling in NSTEMI and in part
o inadequate visualization with current CE-MRI tech-
ology. Both likely play a role. Several additional reasons
ay also contribute. First, time-release curves of large
n Various Categories
Infarct Size in Various Categories
TnT Peak TnT D4
(0.38–0.81), n 31 0.75† (0.5–0.88), n 27
(0.17–0.73), n 30 0.36† (0.06–0.66), n 24
(0.45–0.86), n 28 0.71 (0.40–0.87), n 21
(0.3–0.78), n 33 0.61 (0.32–0.79), n 30
(0.14–0.71), n 30 0.61 (0.28–0.81), n 25
(0.25–0.45), n 31 0.2 (0.21–0.54), n 26
g 95% confidence intervals. *p  0.0042 for the difference between
een large and small MI regarding cTnT AUC; ‡p  0.0034 for the
ndependent Predictors of Infarct Size
Table 3 Independent Predictors of Infarct Size
-Coefficient OR 95% CI p Value
Age above mean (60.4 yrs)
(yes/no)
0.89 2.43 0.6–9.8 0.2
Nonanterior vs. anterior MI
(yes/no)
0.1 0.9 0.24–3.4 0.87
STEMI vs. NSTEMI (yes/no) 1.51 4.52 1.18–17.33 0.028
cTnT on D4 above median
(1.27 g/l) (yes/no)
1.496 4.46 1.18–16.8 0.027
I  confidence interval; OR  odds ratio; STEMI  ST-segment elevation myocardial infarction;
STEMI  non–ST-segment myocardial infarction; other abbreviations as in Tables 1 and 2.ize i
s of
0.65
0.5
0.71
0.59
0.47
0.12
spondin
ce betwtions as in Table 1.
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January 22, 2008:307–14 MRI and cTnT Infarct SizeTEMI differ markedly from small NSTEMI or microinfarcts
nd thus may have an impact on serial measurement algo-
ithms, likely because of fluctuations in perfusion and thus
ariable release of marker. Thus, single-point measurements,
or example, for peak, are less unequivocal and occur earlier for
STEMI (48 or 72 h) than for STEMI (72 or 96 h). This
atter finding is consistent with the prior report of earlier
eaking of markers in patients with NSTEMI of Morrison
t al (33). Second, NSTEMI comprises a heterogenous group
f AMI, including strictly posterior AMI, owing to occlusion
f the left circumflex artery as well as microinfarcts, which
ay hamper optimal timing even within the class of
STEMI. Third, image resolution of MRI may be too low
o allow visualization of very small infarcts or impair
ccurate quantification of small infarcts. Other possible
easons for incorrect quantification of small infarcts by
E-MRI include partial volume effects and higher intra-
nd interobserver variability at the low end of spatial
esolution.
Although not addressed in the present study, as we had
ery few patients with prior AMI, it is likely that troponin
nd CMR will not correlate nearly as closely in patients with
rior AMI than in those with first AMI because CE-MRI
ill measure both areas of damage. However, this would
uggest synergism between the 2 methods, with 1 providing
n estimate of the most recent insult and CMR integrating
amage over time.
onclusions
ingle measurement of cTnT on any of the first 4 days,
articularly on day 4 after onset of AMI, gives a good
stimation of infarct size. Single-point measurements are
onvenient, easy, and inexpensive and may gain clinical
cceptance because they are as effective as serial measure-
ents. However, our findings may not be extrapolated to
ery small AMI unless imaging technologies have improved
o allow exact visualization of small infarct areas. In addi-
ion, more efforts are required to refine sampling protocols
n the heterogenous class of NSTEMI.
eprint requests and correspondence: Dr. Allan S. Jaffe, Mayo
linic and Mayo Medical School, CV Division, Gonda 5, 200
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